2023 Guidance and Q3 Earnings
Continuing operations basis for guidance
2022
2023
Q1
Q2
Q3
Q4
FY
Q1
Q2
Q3
YTD
Including COVID-19 solutions
Sales (£m)
7,190
6,929
7,829
7,376
29,324
6,951
7,178
8,147
22,276
Operating profit (£m)
1,943
2,008
2,605
1,595
8,151
2,092
2,170
2,772
7,034
Operating margin
27.0%
29.0%
33.3%
21.6%
27.8%
30.1%
30.2%
34.0%
31.6%
Earnings per share (pence) post-share
32.3
34.7
46.9
25.8
139.7
37.0
38.8
50.4
126.2
consolidation
COVID-19 solutions impact
Sales (£m)
1,307
466
Operating profit (£m)
194
58
དྷུབ
417
183
2,373
132
41
1
174
141
69
462
118
57
(4)
171
Earnings per share (pence) post-share
4.1
1.2
2.9
1.5
9.7
2.5
1.2
(0.1)
3.6
consolidation
Excluding COVID-19 solutions impact
Sales (£m)
5,883
6,463
7,412
7,193
26,951
6,819
7,137
8,146
22,102
Operating profit (£m)
1,749
1,950
2,464
1,526
7,689
1,974
2,113
2,776
6,863
Operating margin
29.7%
30.2%
33.2%
21.2%
28.5%
28.9%
29.6%
34.1%
31.1%
Earnings per share (pence) post-share
consolidation
28.2
33.5
44.0
24.3
130.0
34.5
37.6
50.5
122.6
GSK
Adjusted results and for continuing operations unless stated otherwise; some figures may not sum due to rounding
32
32View entire presentation